Print Close

Function Improvement in Right Middle Frontal Gyrus: Indicators of Symptom Relief in Schizophrenia

Poster No:

377

Submission Type:

Abstract Submission

Authors:

Weiyi Han¹^,2^,3, Xuzhen Liu¹^,2^,3, Kang Liu¹^,2^,3, Xue Li¹^,2^,3, Anran Chen¹^,2^,3, song liu¹^,2^,3, Luxian Lv¹^,2^,3, Wenqiang Li¹^,2^,3, Yongfeng Yang¹^,2^,3

Institutions:

¹Department of Psychiatry, Henan Mental Hospital, The Second Affiliated Hospital of Xinxiang Medical University, Xinxiang, China, ²Henan Key Lab of Biological Psychiatry, Xinxiang Medical University, International Joint Research Laboratory for Psychiatry and Neuroscience of Henan, Xinxiang, China, ³Henan Collaborative Innovation Center of Prevention and Treatment of Mental Disorder, Xinxiang, China

First Author:

Weiyi Han
Department of Psychiatry, Henan Mental Hospital, The Second Affiliated Hospital of Xinxiang Medical University|Henan Key Lab of Biological Psychiatry, Xinxiang Medical University, International Joint Research Laboratory for Psychiatry and Neuroscience of Henan|Henan Collaborative Innovation Center of Prevention and Treatment of Mental Disorder
Xinxiang, China|Xinxiang, China|Xinxiang, China

Co-Author(s):

Xuzhen Liu
Department of Psychiatry, Henan Mental Hospital, The Second Affiliated Hospital of Xinxiang Medical University|Henan Key Lab of Biological Psychiatry, Xinxiang Medical University, International Joint Research Laboratory for Psychiatry and Neuroscience of Henan|Henan Collaborative Innovation Center of Prevention and Treatment of Mental Disorder
Xinxiang, China|Xinxiang, China|Xinxiang, China

Kang Liu
Department of Psychiatry, Henan Mental Hospital, The Second Affiliated Hospital of Xinxiang Medical University|Henan Key Lab of Biological Psychiatry, Xinxiang Medical University, International Joint Research Laboratory for Psychiatry and Neuroscience of Henan|Henan Collaborative Innovation Center of Prevention and Treatment of Mental Disorder
Xinxiang, China|Xinxiang, China|Xinxiang, China

Xue Li
Department of Psychiatry, Henan Mental Hospital, The Second Affiliated Hospital of Xinxiang Medical University|Henan Key Lab of Biological Psychiatry, Xinxiang Medical University, International Joint Research Laboratory for Psychiatry and Neuroscience of Henan|Henan Collaborative Innovation Center of Prevention and Treatment of Mental Disorder
Xinxiang, China|Xinxiang, China|Xinxiang, China

Anran Chen
Department of Psychiatry, Henan Mental Hospital, The Second Affiliated Hospital of Xinxiang Medical University|Henan Key Lab of Biological Psychiatry, Xinxiang Medical University, International Joint Research Laboratory for Psychiatry and Neuroscience of Henan|Henan Collaborative Innovation Center of Prevention and Treatment of Mental Disorder
Xinxiang, China|Xinxiang, China|Xinxiang, China

song liu
Department of Psychiatry, Henan Mental Hospital, The Second Affiliated Hospital of Xinxiang Medical University|Henan Key Lab of Biological Psychiatry, Xinxiang Medical University, International Joint Research Laboratory for Psychiatry and Neuroscience of Henan|Henan Collaborative Innovation Center of Prevention and Treatment of Mental Disorder
Xinxiang, China|Xinxiang, China|Xinxiang, China

Luxian Lv
Department of Psychiatry, Henan Mental Hospital, The Second Affiliated Hospital of Xinxiang Medical University|Henan Key Lab of Biological Psychiatry, Xinxiang Medical University, International Joint Research Laboratory for Psychiatry and Neuroscience of Henan|Henan Collaborative Innovation Center of Prevention and Treatment of Mental Disorder
Xinxiang, China|Xinxiang, China|Xinxiang, China

Wenqiang Li
Department of Psychiatry, Henan Mental Hospital, The Second Affiliated Hospital of Xinxiang Medical University|Henan Key Lab of Biological Psychiatry, Xinxiang Medical University, International Joint Research Laboratory for Psychiatry and Neuroscience of Henan|Henan Collaborative Innovation Center of Prevention and Treatment of Mental Disorder
Xinxiang, China|Xinxiang, China|Xinxiang, China

Yongfeng Yang
Department of Psychiatry, Henan Mental Hospital, The Second Affiliated Hospital of Xinxiang Medical University|Henan Key Lab of Biological Psychiatry, Xinxiang Medical University, International Joint Research Laboratory for Psychiatry and Neuroscience of Henan|Henan Collaborative Innovation Center of Prevention and Treatment of Mental Disorder
Xinxiang, China|Xinxiang, China|Xinxiang, China

Introduction:

Results from functional magnetic resonance imaging (fMRI) studies indicate abnormal brain function in patients with schizophrenia (SZ). To date, most studies have been cross-sectional observational studies, and objective markers from longitudinal studies are still scarce.Therefore, this study conducted an objective marker research on long-term follow-up patients with SZ.

Methods:

A total of 110 patients with SZ were recruited and underwent fMRI scans at baseline and week 8 of antipsychotic treatment, while 100 healthy controls (HCs) underwent baseline scans for comparison. The Positive and Negative Syndrome Scale (PANSS) and MATRICS Consensus Cognitive Battery (MCCB) were used to assess psychiatric symptoms and cognitive function in patients with SZ. A three-factor model or five-factor model is derivable from the PANSS. Individual voxel-based brain regional homogeneity (ReHo), amplitude of low-frequency fluctuations (ALFF), and functional connectivity (FC) were analyzed.

Results:

Compared to HCs at baseline, the ALFF value in the right middle frontal gyrus (MFG) was decreased. After 8 weeks of treatment, patients with SZ showed an increase in the ALFF and ReHo value of the right MFG and superior frontal gyrus, dorsolateral (SFGdor)(Figure 1). As shown in Figure 2,in the PANSS three-factor model, an increase in the ReHo value of the right SFGdor was associated with a decrease in the positive factor score after 8 weeks of treatment in patients with SZ ( r = 0.265, p = 0.009, FDR = 0.027). In the PANSS five-factor model, an increase in the ALFF value of the right MFG was associated with a decrease in the cognitive factor score after 8 weeks of treatment in patients with SZ ( r = -0.231, p = 0.023, FDR = 0.115), an increase in ReHo value for the right MFG correlated with a decrease in trail making test score ( r = -0.209, p = 0.040, FDR = 0.28), an increase in the ReHo value of the right SFGdor correlated with an decrease in the positive factor score ( r = -0.257, p = 0.011, FDR = 0.055). An increase in the ReHo value of the right MFG correlated with a decrease in the depression factor score ( r = -0.250, p = 0.013, FDR = 0.065).

·Comparison of ALFF and ReHo before and after SZ treatment.

·Correlation analysis of PANSS with ReHo, ALFF.

Conclusions:

This study provide a novel evidence that the enhancement of functional activity in the right MFG after short-term antipsychotic medication may be a biomaker of the improvement of cognitive function in SZ patients. Meanwhile, increased functional activity of SFGdor may be predict the amelioration of positive symptoms.

Disorders of the Nervous System:

Psychiatric (eg. Depression, Anxiety, Schizophrenia) ¹

Emotion, Motivation and Social Neuroscience:

Social Cognition

Modeling and Analysis Methods:

fMRI Connectivity and Network Modeling ²

Keywords:

FUNCTIONAL MRI

Schizophrenia

Other - middle frontal gyrus, regional homogeneity, amplitude of low-frequency fluctuations

^1|2Indicates the priority used for review

Abstract Information

By submitting your proposal, you grant permission for the Organization for Human Brain Mapping (OHBM) to distribute your work in any format, including video, audio print and electronic text through OHBM OnDemand, social media channels, the OHBM website, or other electronic publications and media.

I accept

The Open Science Special Interest Group (OSSIG) is introducing a reproducibility challenge for OHBM 2025. This new initiative aims to enhance the reproducibility of scientific results and foster collaborations between labs. Teams will consist of a “source” party and a “reproducing” party, and will be evaluated on the success of their replication, the openness of the source work, and additional deliverables. Click here for more information. Propose your OHBM abstract(s) as source work for future OHBM meetings by selecting one of the following options:

I am submitting this abstract as an original work to be reproduced. I am available to be the “source party” in an upcoming team and consent to have this work listed on the OSSIG website. I agree to be contacted by OSSIG regarding the challenge and may share data used in this abstract with another team.

Please indicate below if your study was a "resting state" or "task-activation” study.

Resting state

Healthy subjects only or patients (note that patient studies may also involve healthy subjects):

Patients

Was this research conducted in the United States?

Were any human subjects research approved by the relevant Institutional Review Board or ethics panel? NOTE: Any human subjects studies without IRB approval will be automatically rejected.

Yes

Were any animal research approved by the relevant IACUC or other animal research panel? NOTE: Any animal studies without IACUC approval will be automatically rejected.

Not applicable

Please indicate which methods were used in your research:

Functional MRI

For human MRI, what field strength scanner do you use?

3.0T

Which processing packages did you use for your study?

SPM

Provide references using APA citation style.

not applicable

UNESCO Institute of Statistics and World Bank Waiver Form

I attest that I currently live, work, or study in a country on the UNESCO Institute of Statistics and World Bank List of Low and Middle Income Countries list provided.